Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

TG Therapeutics, Inc. (TGTX) had Revenue of $240.34M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$240.34M
Net Income	$7.78M
Cost of Goods Sold	$41.19M
Gross Profit	$199.14M
Operating Expenses	$218.66M
Operating Income	$21.67M
Non-Operating Income/Expense	$-11.44M
Pre-Tax Income	$10.23M
Normalized Pre-Tax Income	$10.23M
Income after Taxes	$7.78M
Income from Continuous Operations	$7.78M
Consolidated Net Income/Loss	$7.78M
Normalized Income after Taxes	$7.78M
EBIT	$21.67M
EBITDA	$21.76M
Weighted-Average Shares Outstanding (Basic)	141.77M
Weighted-Average Shares Outstanding (Diluted)	157.28M
Earnings per Share (EPS) (Basic)	$0.05
Earnings per Share (EPS) (Diluted)	$0.05
Balance Sheet Financials
Current Assets	$1.15B
Property, Plant, and Equipment	--
Long-Term Assets	$493.94M
Total Assets	$1.64B
Current Liabilities	$268.49M
Long-Term Debt	$745.39M
Long-Term Liabilities	$767.05M
Total Liabilities	$1.04B
Common Equity	$604.08M
Tangible Shareholders Equity	$604.08M
Shareholders Equity	$604.08M
Common Shares Outstanding	153.08M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$21.37M
Cash Flow from Investing Activities	$-8.83M
Cash Flow from Financial Activities	$390.91M
Beginning Cash	$80.49M
End Cash	$483.94M
Increase/Decrease in Cash	$403.45M
Stock-Based Compensation	$47.83M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.27
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.55
Debt to Equity Ratio	1.23
Gross Margin	82.86%
Operating Margin	9.02%
EBIT Margin	9.02%
EBITDA Margin	--
Pre-Tax Profit Margin	4.26%
Profit Margin	3.24%
Free Cash Flow	$21.02M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.28
Receiveable Turnover	0.60
Days Sales in Receivables	150.38
Return on Equity	1.29%
Return on Tangible Equity	1.29%
Return on Assets	0.47%
Return on Investments	0.58%
Book Value Per Share	$3.95
Free Cash Flow per Share	$0.13
Operating Cash Flow per Share	$0.14

Data from Zacks Investment Research, Inc.